Tdspharm Co., Ltd. researches (464280) fair value: what the stock is really worth
As of Sep 23, 2026: fair value of Tdspharm Co., Ltd. researches KRW 13,672, price KRW 5,440, upside +151.3%, quality 41 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Tdspharm Co., Ltd. researches for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
Tdspharm Co., Ltd. researches, develops, and produces pharmaceuticals and cosmetics in South Korea and internationally. It offers general medicines, prescription drugs, and non-medicinal products. The company was founded in 2002 and is based in Seongnam-si, South Korea.
Stock analysis
Tdspharm Co., Ltd. researches (464280) currently trades at 5,440 KRW, while our model-based Fair Value estimate is 13,672 KRW, implying the stock looks roughly 60.2% undervalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of 13,710 KRW per share, and 11 of the 12 models we run sit above the 5,440 KRW price.
Bear case: the Asset-Based group reads lowest at 5,420 KRW, and 1 of the 12 models stay below the price. Evidence for this calculation is low.
Scenario range: 9,597 KRW (bear) to 17,090 KRW (bull), the price of 5,440 KRW sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 41/100 (below-average quality), in the Healthcare sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Tdspharm Co., Ltd. researches reported revenue of 27.6B KRW in FY2025 versus 19.8B KRW in FY2021, a compound +8.7%/yr. Reported net income was 4.3B KRW in FY2025, compounding +20.0%/yr from FY2021.
Key figures
Market cap 28.8B KRW (≈ $20.1M) · P/S ratio 0.96 · Net margin 15.5% · Return on equity 12.2% · Return on assets (EBIT) 10.0% · Operating margin 16.7% · Revenue (TTM) 30.4B KRW · Revenue growth (YoY) +52.9%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 48 out of 100 (low confidence).
What moves the price
The share trades about 48% below its 52-week high and 20% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −2% fair-value upside, at 151%, 464280 screens cheaper than that median.
Fair Value models
Bear 9,597 KRWFair Value 13,672 KRWBull 17,090 KRW
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.35/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+0.4%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+2.6%
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years), in KRW ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in KRW: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
+15.7%
Earnings growth per share plus dividend.
Earnings per share, growth per year+15.7%
Dividend (yield on the price)0.0%
Profit margin 2021 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.12% → 14%
Compare Tdspharm Co., Ltd. researches with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - General · 74 stocks
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Tdspharm Co., Ltd. researches (464280) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of 13,672 KRW versus a price of 5,440 KRW, about +151% upside (undervalued).
What is the fair value of 464280?
Our model-based fair value for Tdspharm Co., Ltd. researches is 13,672 KRW (as of Sep 24, 2026), built from audited fundamentals. The current price: 5,440 KRW.
What is the quality score of 464280?
Tdspharm Co., Ltd. researches has a Quality Score of 41/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Tdspharm Co., Ltd. researches (464280)?
Our model-based price target is the fair value of 13,672 KRW (as of Sep 24, 2026) from 12 valuation models. Cautious scenario 9,597 KRW, optimistic scenario 17,090 KRW. It is a calculation from audited fundamentals, not an analyst target.
What is the Tdspharm Co., Ltd. researches stock forecast for 2026?
Our models put fair value at 13,672 KRW, about +151% upside versus a price of 5,440 KRW (undervalued). Cautious scenario 9,597 KRW, optimistic scenario 17,090 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of Tdspharm Co., Ltd. researches (464280)?
Tdspharm Co., Ltd. researches reported trailing-twelve-month revenue of about 30.4B KRW (latest available figure, as of Sep 24, 2026).
What is the intrinsic value of Tdspharm Co., Ltd. researches (464280)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Tdspharm Co., Ltd. researches it is 13,672 KRW per share (as of Sep 24, 2026), against a price of 5,440 KRW. It is the blended result of 12 valuation models (cash flow, earnings, asset, dividend).
Is Tdspharm Co., Ltd. researches stock overvalued or undervalued in 2026?
As of Sep 24, 2026, 464280 trades below its calculated fair value: price 5,440 KRW, fair value 13,672 KRW, a gap of about +151% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 464280?
No. The price is what the market pays today (5,440 KRW); the fair value is what the company's own numbers justify (13,672 KRW). For Tdspharm Co., Ltd. researches the two are 8,232 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is Tdspharm Co., Ltd. researches worth?
The market values Tdspharm Co., Ltd. researches at about 28.8B KRW (market capitalisation, as of Sep 24, 2026). Per share that is 5,440 KRW; our models calculate a fair value of 13,672 KRW per share.
What do the bullish and bearish scenarios say about 464280?
Our models span a range for Tdspharm Co., Ltd. researches: cautious scenario 9,597 KRW, base 13,672 KRW, optimistic 17,090 KRW per share (as of Sep 24, 2026, price 5,440 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Tdspharm Co., Ltd. researches (464280)?
Balance-sheet figures for Tdspharm Co., Ltd. researches (as of Sep 24, 2026): return on equity 12.2%. They feed the Quality Score of 41/100, which measures business quality independently of the share price.
How far is 464280 from its 52-week high?
Tdspharm Co., Ltd. researches trades at 5,440 KRW, about 48% below its 52-week high of 10,500 KRW and 20% above the low of 4,525 KRW (as of Sep 23, 2026). Distance from the high says nothing about value: that is what the fair value of 13,672 KRW is for.
Which stocks are comparable to Tdspharm Co., Ltd. researches?
From the same area (Healthcare) we also value Eli Lilly and Company, Johnson & Johnson,, AbbVie Inc, Roche Holding, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Tdspharm Co., Ltd. researches stock attractive at the current price?
The data as of Sep 24, 2026: price 5,440 KRW, calculated fair value 13,672 KRW (+151%), Quality Score 41/100, from 12 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 464280 calculated?
We run Tdspharm Co., Ltd. researches through 12 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 13,672 KRW, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.0 % above its aggregate fair value. Tdspharm Co., Ltd. researches currently trades 151 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Tdspharm Co., Ltd. researches (464280)?
The closing price on Sep 23, 2026 was 5,440 KRW. Our model-based fair value is 13,672 KRW, about +151% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Tdspharm Co., Ltd. researches right now?
The large discount to fair value meets weak quality (41/100). That raises the risk this is a value trap rather than a bargain. The price is below even our cautious bear case (9,597 KRW). The market is more pessimistic than our downside scenario. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
Key figures of Tdspharm Co., Ltd. researches
How large is the market capitalisation of Tdspharm Co., Ltd. researches (464280)?
The market capitalisation of Tdspharm Co., Ltd. researches is 28.8B KRW (≈ $20.1M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Tdspharm Co., Ltd. researches (464280)?
The price-to-sales ratio of Tdspharm Co., Ltd. researches is 0.96 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the net margin of Tdspharm Co., Ltd. researches (464280)?
The net margin of Tdspharm Co., Ltd. researches is 15.5% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Tdspharm Co., Ltd. researches (464280)?
The return on equity (ROE) of Tdspharm Co., Ltd. researches is 12.2% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Tdspharm Co., Ltd. researches (464280)?
On an EBIT basis the return on assets of Tdspharm Co., Ltd. researches is 10.0% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Tdspharm Co., Ltd. researches (464280)?
The operating margin of Tdspharm Co., Ltd. researches is 16.7% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Tdspharm Co., Ltd. researches (464280)?
Revenue at Tdspharm Co., Ltd. researches is growing +52.9% versus a year earlier (3y avg +2.6%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Tdspharm Co., Ltd. researches (464280)?
Earnings per share at Tdspharm Co., Ltd. researches are growing +214% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Tdspharm Co., Ltd. researches (464280) generate?
The free cash flow of Tdspharm Co., Ltd. researches is −9.1B KRW (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Tdspharm Co., Ltd. researches (464280) carry?
The net debt of Tdspharm Co., Ltd. researches is 6.4B KRW (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Tdspharm Co., Ltd. researches in the live analysis
One click puts Tdspharm Co., Ltd. researches on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
